Table 3 Subgroup analysis of the associations between 90-day all-cause mortality and the platelet-to-lymphocyte ratio

AKI stage

0.301

 Stage 1

7137/1740

1.23 (1.05–1.43)^a

1.00

1.22 (1.08–1.38)^a

 Stage 2

2436/1474

1.23 (1.02–1.50)^b

1.00

1.09 (0.92–1.30)

 Stage 3

1286/876

1.38 (1.04–1.82)

1.00

1.30 (0.99–1.72)

0.906

 Yes

326/177

1.45 (0.97–2.17)

1.00

1.31 (0.86–2.01)

 No

10,533/2935

1.24 (1.11–1.39)^c

1.00

1.17 (1.06–1.29)^a

Age, years

<0.001

  < 65

4686/1000

1.37 (1.16–1.62)^c

1.00

1.06 (0.88–1.27)

  ≥ 65

6035/2054

1.09 (0.94–1.27)

1.00

1.25 (1.12–1.40)^c

Sex

0.386

 Male

5931/1741

1.22 (1.06–1.41)^a

1.00

1.24 (1.09–1.41)^c

 Female

4928/1371

1.26 (1.06–1.49)^a

1.00

1.13 (0.98–1.31)

Ethnicity

0.409

 White

7564/2134

1.25 (1.09–1.44)^c

1.00

1.19 (1.06–1.33)^a

 Black

1216/254

1.24 (0.84–1.81)

1.00

1.33 (0.92–1.93)

 Other

2079/724

1.21 (0.98–1.49)

1.00

1.11 (0.90–1.36)

PO₂, mmHg

0.310

  < 167.3

6433/2108

1.29 (1.14–1.47)^c

1.00

1.21 (1.08–1.35)^a

 ≥1  67.3

3502/870

1.16 (0.95–1.42)

1.00

1.21 (1.00–1.47)

GCS score

0.938

  < 11.4

4101/1387

1.25 (1.07–1.46)^a

1.00

1.21 (1.05–1.39)

  ≥ 11.4

6499/1663

1.24 (1.06–1.45)^a

1.00

1.18 (1.04–1.35)^b

Heart rate, beats/min

0.001

  < 89.4

5811/1503

1.08 (0.92–1.28)

1.00

1.29 (1.12–1.48)^c

  ≥ 89.4

4880/1575

1.39 (1.20–1.61)^c

1.00

1.10 (0.96–1.26)

SBP, mmHg

0.187

  < 122.6

5596/1885

1.28 (1.12–1.46)^c

1.00

1.15 (1.02–1.30)^b

  ≥ 122.6

4800/1070

1.18 (0.97–1.43)

1.00

1.26 (1.07–1.47)^a

Potassium, mmol/L

0.633

  < 4.39

6158/1667

1.24 (1.07–1.44)^a

1.00

1.19 (1.04–1.36)^a

  ≥ 4.39

4692/1443

1.24 (1.05–1.47)^b

1.00

1.22 (1.06–1.40)^a

Creatinine, mg/dl

0.816

  < 2.28

7809/2128

1.29 (1.13–1.47)^c

1.00

1.21 (1.08–1.35)^a

  ≥ 2.28

3048/982

1.17 (0.96–1.44)

1.00

1.15 (0.97–1.37)

Urine output, ml/24 h

0.083

  < 1807

7057/2309

1.28 (1.13–1.45)^c

1.00

1.13 (1.02–1.26)^b

  ≥ 1807

3300/641

1.17 (0.92–1.47)

1.00

1.38 (1.12–1.69)^a

BUN, mg/dl

0.615

  < 39.2

6887/1737

1.30 (1.13–1.50)^c

1.00

1.23 (1.08–1.40)^a

  ≥ 39.2

3972/1375

1.19 (1.00–1.41)

1.00

1.17 (1.01–1.35)^b

Vasopressin use

0.549

 Yes

4619/1784

1.29 (1.13–1.48)^c

1.00

1.24 (1.09–1.40)^a

 No

6240/1328

1.17 (0.96–1.42)

1.00

1.11 (0.95–1.29)

Ventilator use

0.216

 Yes

5907/2098

1.26 (1.12–1.43)^c

1.00

1.17 (1.05–1.31)^a

 No

4952/1014

1.21 (0.95–1.54)

1.00

1.21 (1.01–1.45)^b

Cardiac arrhythmias

0.671

 Yes

3015/1040

1.13 (0.91–1.39)

1.00

1.19 (1.02–1.40)^b

 No

7844/2072

1.29 (1.13–1.47)^c

1.00

1.19 (1.06–1.34)^a

Valvular disease

0.986

 Yes

1145/339

0.75 (0.51–1.10)

1.00

1.37 (1.01–1.87)^b

 No

9714/2773

1.31 (1.17–1.47)^c

1.00

1.18 (1.07–1.31)^a

Pulmonary circulation

0.320

 Yes

670/199

1.20 (0.76–1.89)

1.00

1.12 (0.76–1.63)

 No

10,189/2913

1.34 (1.11–1.39)^c

1.00

1.18 (1.07–1.31)^a

Chronic pulmonary disease

0.289

 Yes

2156/638

0.97 (0.72–1.29)

1.00

1.14 (0.94–1.38)

 No

8703/2474

1.29 (1.15–1.46)^c

1.00

1.21 (1.08–1.34)^a

Liver disease

0.919

 Yes

900/410

1.13 (0.89–1.45)

1.00

1.08 (0.78–1.50)

 No

9959/2702

1.26 (1.12–1.42)^c

1.00

1.21 (1.09–1.33)^c

Lymphoma

0.101

 Yes

231/102

1.66 (0.94–2.93)

1.00

1.79 (0.97–3.30)

 No

10,628/3010

1.23 (1.10–1.37)^c

1.00

1.18 (1.07–1.30)^a

Metastatic cancer

0.901

 Yes

545/317

0.97 (0.63–1.49)

1.00

1.11 (0.84–1.45)

 No

10,314/2795

1.26 (1.12–1.41)^c

1.00

1.15 (1.04–1.27)^a

Solid tumor

0.605

 Yes

752/333

1.22 (0.82–1.81)

1.00

1.21 (0.91–1.60)

 No

10,107/2779

1.24 (1.10–1.38)^c

1.00

1.18 (1.07–1.31)^a

Deficiency anemias

0.852

 Yes

1676/378

1.15 (0.91–1.46)

1.00

1.12 (0.77–1.53)

 No

9183/2734

1.25 (1.10–1.39)

1.00

1.20 (1.07–1.33)

Cardiac surgery

0.207

 Yes

1864/635

1.16 (0.92–1.45)

1.00

1.24 (1.01–1.52)^b

 No

8995/2477

1.30 (1.14–1.47)^c

1.00

1.16 (1.04–1.29)^a